{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:54:19Z","timestamp":1781690059885,"version":"3.54.5"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2\u2010targeted antibody\u2013drug conjugate (ADC) trastuzumab deruxtecan (T\u2010DXd) is eliminated by hepatic uptake via OATP1B1\/3, metabolism by CYP3A, biliary excretion via P\u2010glycoprotein and breast cancer resistance protein, and urinary excretion. In a clinical drug\u2013drug interaction (DDI) study between T\u2010DXd and ritonavir (a strong cytochrome P450 [CYP] 3A\/organic anion transporting polypeptide 1B inhibitor) or itraconazole (a strong CYP3A inhibitor), a 1.2\u2010fold increase in DXd exposure was observed. In this study, a physiologically based pharmacokinetic (PBPK) model of T\u2010DXd was constructed to quantitatively describe the pharmacokinetics (PK) of DXd and the DDI of DXd released from T\u2010DXd. The minimal ADC PBPK model was developed to describe both intact ADC and payload PK using in\u00a0vitro data of DXd and clinical PK data after T\u2010DXd administration. The developed model reasonably described the PK of T\u2010DXd and DXd after intravenous administration of T\u2010DXd. The main elimination pathway of DXd was estimated to be biliary excretion, followed by urinary excretion, with metabolism contributing to a lesser extent. DDIs with ritonavir and itraconazole simulated by the PBPK model reproduced the clinical DDI study results, indicating that the impact of concomitant medications was not clinically meaningful. These findings suggest that this model may potentially be used for DDI evaluation of future DXd\u2010containing ADCs, aiding in the prediction of DDIs under different scenarios and in specific populations.<\/jats:p>","DOI":"10.1002\/psp4.70284","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:59:29Z","timestamp":1781071169000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Pharmacokinetic Model to Predict Drug\u2013Drug Interactions With the Antibody\u2013Drug Conjugate Trastuzumab Deruxtecan"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-5911","authenticated-orcid":false,"given":"Akiko","family":"Watanabe","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-5173","authenticated-orcid":false,"given":"Katherine L.","family":"Gill","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies Division Certara UK Limited  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-5363","authenticated-orcid":false,"given":"Kuan\u2010Fu","family":"Chen","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies Division Certara UK Limited  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies Division Certara UK Limited  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-4350","authenticated-orcid":false,"given":"Mailys","family":"De Sousa Mendes","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies Division Certara UK Limited  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies Division Certara UK Limited  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Kotsuma","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2448"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1531158"},{"key":"e_1_2_9_6_1","unstructured":"Z.Lu H.Li R.Wada et\u00a0al. \u201cPII\u2010117 \u2013 Exposure\u2010Response of Trastuzumab Deruxtecan (T\u2010DXD) in Subjects With HER2\u2010Low Metastatic Breast Cancer \u201d ASCPT 2024 Annual Meeting; The Broadmoor Colorado Springs; March 27\u201329 2024. Abstract accessed September 25 2025 https:\/\/ascpt2024.eventscribe.net\/fsPopup.asp?PosterID=642997&mode=posterInfo."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1560"},{"key":"e_1_2_9_8_1","unstructured":"US FDA Center for Drug Evaluation and Research \u201cClinical Pharmacology and Biopharmaceutics Review(s) \u201d Application Number 125388Orig1s000; BLA 125388 and 125399 Brentuximab vedotin 2011 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125388Orig1s000ClinPharmR.pdf."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0182-x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1718"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09877-5"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30604-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9640-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0097-y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.974423"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903296"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9065-1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1008353"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1994.74.1.163"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2014.11.002"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.042275"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2018.12.017"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1013"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2757"},{"key":"e_1_2_9_26_1","unstructured":"Center for Drug Evaluation and Research \u201cNDA\/BLA Multi\u2010Disciplinary Review and Evaluation BLA 761394 Trade Name (Datopotamab Deruxtecan\u2010Dlnk) \u201d accessed May 1 2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761394Orig1s000MultidisciplineR.pdf."}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.70284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:08:25Z","timestamp":1781687305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/psp4.70284"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70284","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70284"}}